HK1009290A1 - A recombinant human factor viii derivative - Google Patents

A recombinant human factor viii derivative

Info

Publication number
HK1009290A1
HK1009290A1 HK98109933A HK98109933A HK1009290A1 HK 1009290 A1 HK1009290 A1 HK 1009290A1 HK 98109933 A HK98109933 A HK 98109933A HK 98109933 A HK98109933 A HK 98109933A HK 1009290 A1 HK1009290 A1 HK 1009290A1
Authority
HK
Hong Kong
Prior art keywords
factor viii
human factor
recombinant human
derivative
dna segment
Prior art date
Application number
HK98109933A
Inventor
Anneli B Almstedt
Eva Maria Hellstrom
Kerstin Larsson
Peter Lind
Helena Inga Sandberg
Jack Spira
Mona Sydow-Backman
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20377785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1009290(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Publication of HK1009290A1 publication Critical patent/HK1009290A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Confectionery (AREA)

Abstract

A DNA sequence coding for a biologically active recombinant human factor VIII derivative, comprising a first DNA segment coding for the 90 kDa chain of human factor VIII and a second DNA segment coding for the 80 kDa chain of human factor VIII, said segments being interconnected by a linker DNA segment coding for a linker peptide of 4 to about 100 amino acid residues of the B domain of human factor VIII, at least 4 of said amino acid residues originating from the C terminal of said domain; recombinant expression vector comprising such DNA sequence; host cells of animal origin transformed with such recombinant expression vector; a process for the manufacture of recombinant human factor VIII derivative; and human factor VIII derivative containing the heavy chain and the light chain linked by metal ion bond. <IMAGE>
HK98109933A 1989-12-15 1998-08-14 A recombinant human factor viii derivative HK1009290A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8904239A SE465222C5 (en) 1989-12-15 1989-12-15 A recombinant human factor VIII derivative and process for its preparation
PCT/SE1990/000809 WO1991009122A1 (en) 1989-12-15 1990-12-06 A recombinant human factor viii derivative

Publications (1)

Publication Number Publication Date
HK1009290A1 true HK1009290A1 (en) 1999-05-28

Family

ID=20377785

Family Applications (2)

Application Number Title Priority Date Filing Date
HK98109933A HK1009290A1 (en) 1989-12-15 1998-08-14 A recombinant human factor viii derivative
HK99104067A HK1019449A1 (en) 1989-12-15 1998-08-14 A recombinant human factor viii derivative

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK99104067A HK1019449A1 (en) 1989-12-15 1998-08-14 A recombinant human factor viii derivative

Country Status (21)

Country Link
EP (3) EP0506757B2 (en)
JP (1) JP2644084B2 (en)
AT (2) ATE232213T1 (en)
AU (1) AU645539B2 (en)
BR (1) BR9007921A (en)
CA (1) CA2071875C (en)
DE (3) DE69034040T2 (en)
DK (2) DK0506757T4 (en)
ES (2) ES2189897T3 (en)
FI (1) FI104260B1 (en)
HK (2) HK1009290A1 (en)
HU (1) HU211504A9 (en)
IE (1) IE904510A1 (en)
LU (1) LU90457I2 (en)
NL (1) NL990035I2 (en)
NO (1) NO309041B1 (en)
NZ (1) NZ236276A (en)
PT (1) PT96208B (en)
SE (1) SE465222C5 (en)
SG (1) SG66753A1 (en)
WO (1) WO1991009122A1 (en)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6060447A (en) * 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
SE468050C (en) * 1991-03-15 1998-04-27 Pharmacia & Upjohn Ab Recombinant human factor VIII derivative
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
DK53792D0 (en) * 1992-04-24 1992-04-24 Novo Nordisk As PROCEDURE FOR PRODUCING PROTEINS
KR100303872B1 (en) * 1992-10-02 2001-11-22 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 Compositions containing coagulation factor formulations, methods for their preparation and use of surfactants as stabilizers
SE9300509D0 (en) * 1993-02-16 1993-02-16 Kabi Pharmacia Ab PEG TREATMENT
SE9301581D0 (en) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab PROTEIN FORMULATION
SE504074C2 (en) * 1993-07-05 1996-11-04 Pharmacia Ab Protein preparation for subcutaneous, intramuscular or intradermal administration
SE9303601D0 (en) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (en) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE503424C2 (en) * 1994-11-14 1996-06-10 Pharmacia Ab Process for purification of recombinant coagulation factor VIII
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
SE9501189D0 (en) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
WO1997003193A1 (en) * 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (en) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
EP1318198B1 (en) * 1996-05-14 2006-03-22 Biovitrum Ab Process for producing a recombinant polypeptide involving the addition of an inhibitor of chymotrypsins to the cell culture medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AU735763B2 (en) * 1997-12-05 2001-07-12 Immune Response Corporation, The Novel vectors and genes exhibiting increased expression
US7820796B2 (en) 1998-03-12 2010-10-26 Genetics Institute, Llc. Methods for producing Factor VIII proteins
US6797505B2 (en) * 1998-05-27 2004-09-28 Cell Genesys, Inc. Recombinant AAV vectors for gene therapy of hemophilia A
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
DE60035260T2 (en) 1999-02-22 2007-10-18 The University Of Connecticut, Farmington NEW ALBUMIN FREE FACTOR VIII FORMULATIONS
SE9901379D0 (en) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
AT409379B (en) 1999-06-02 2002-07-25 Baxter Ag MEDIUM FOR PROTEIN- AND SERUM-FREE CELL CULTURE
CA2404163C (en) * 2000-03-22 2009-09-29 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
JP2005532057A (en) 2002-07-09 2005-10-27 バクスター・インターナショナル・インコーポレイテッド Animal protein-free medium for culturing cells
EP1596887B1 (en) * 2003-02-26 2022-03-23 Nektar Therapeutics Polymer-factor viii moiety conjugates
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
EP2298926A1 (en) 2003-09-30 2011-03-23 The Trustees of The University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP1814573B1 (en) 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP2371856B1 (en) 2004-11-12 2022-05-18 Bayer HealthCare LLC Site-directed modification of FVIII
ES2449195T3 (en) 2005-01-10 2014-03-18 Ratiopharm Gmbh Glycopegylated granulocyte colony stimulating factor
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP3409296A1 (en) 2005-04-07 2018-12-05 The Trustees of the University of Pennsylvania Method of increasing the function of an aav vector
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP2522717B1 (en) 2006-01-04 2014-04-02 Baxter International Inc Oligopeptide-free cell culture media
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7683158B2 (en) 2006-03-31 2010-03-23 Baxter International Inc. Pegylated factor VIII
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
CN101516388B (en) 2006-07-21 2012-10-31 诺和诺德公司 Glycosylation of peptides via O-linked glycosylation sequences
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
EP2101821B1 (en) 2006-12-15 2014-08-13 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
KR101389376B1 (en) 2007-02-23 2014-04-29 에스케이케미칼주식회사 Process for producing and purifying factor viii and its derivatives
KR20100016160A (en) 2007-04-03 2010-02-12 바이오제너릭스 에이지 Methods of treatment using glycopegylated g-csf
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
DK2235197T3 (en) 2007-12-27 2017-10-09 Baxalta GmbH Methods of cell culture
ES2476690T3 (en) 2008-02-27 2014-07-15 Novo Nordisk A/S Factor VIII conjugated molecules
EP2393828B1 (en) 2009-02-03 2016-10-12 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
NO2440239T3 (en) 2009-06-09 2018-02-10
EP2459224B1 (en) 2009-07-27 2016-06-01 Baxalta GmbH Blood coagulation protein conjugates
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG10201401194VA (en) 2009-07-27 2014-07-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
NZ597600A (en) 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
WO2011028229A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
GB0915481D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable manufacture of factor V111
EP4382170A2 (en) 2009-12-06 2024-06-12 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
SG10201908848RA (en) 2010-03-29 2019-10-30 Univ Pennsylvania Pharmacologically induced transgene ablation system
EP3508573A1 (en) 2010-07-09 2019-07-10 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
AU2011274423B2 (en) 2010-07-09 2016-02-11 Bioverativ Therapeutics Inc. Chimeric clotting factors
CN103209992A (en) * 2010-09-15 2013-07-17 诺沃—诺迪斯克有限公司 Factor viii variants having a decreased cellular uptake
NZ612320A (en) 2010-12-22 2015-06-26 Baxter Healthcare Sa Materials and methods for conjugating a water soluble fatty acid derivative to a protein
PL2675902T3 (en) 2011-02-17 2019-08-30 The Trustees Of The University Of Pennsylvania Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
AU2012267484B2 (en) 2011-06-10 2017-03-23 Bioverativ Therapeutics Inc. Pro-coagulant compounds and methods of use thereof
AR087091A1 (en) 2011-07-08 2014-02-12 Biogen Idec Hemophilia Inc CHEMICAL AND HYBRID POLYPEPTIDES OF FACTOR VIII, AND ITS METHODS OF USE
EA028914B1 (en) 2011-07-25 2018-01-31 Байоджен Хемофилия Инк. Assays to monitor bleeding disorders
WO2013098676A1 (en) 2011-12-30 2013-07-04 Grifols, S.A. Method for purifying factor viii
LT2804623T (en) 2012-01-12 2019-12-10 Bioverativ Therapeutics Inc Chimeric factor viii polypeptides and uses thereof
EA038705B1 (en) 2012-01-12 2021-10-07 Биовератив Терапьютикс Инк. Methods of reducing immunogenicity against blood coagulation factor viii in patients undergoing factor viii therapy
RS63870B1 (en) 2012-02-15 2023-01-31 Bioverativ Therapeutics Inc Factor viii compositions and methods of making and using same
HUE043537T2 (en) 2012-02-15 2019-08-28 Bioverativ Therapeutics Inc Recombinant factor viii proteins
JP2015521589A (en) 2012-06-08 2015-07-30 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Procoagulant compounds
JP2015525222A (en) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Chimeric coagulation factor
WO2014008480A2 (en) 2012-07-06 2014-01-09 Biogen Idec Ma Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
LT2882450T (en) 2012-07-11 2020-03-25 Bioverativ Therapeutics Inc. Factor viii complex with xten and von willebrand factor protein, and uses thereof
RU2500818C1 (en) * 2012-07-19 2013-12-10 Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") RECOMBINANT PLASMID DNA pAP227 CODING POLYPEPTIDE OF RECOMBINANT FACTOR VIII OF HUMAN BLOOD COAGULABILITY, LINE OF CELLS Cricetulus griseus CHO, 2H5-PRODUCER OF RECOMBINANT FACTOR VIII OF HUMAN BLOOD COAGULABILITY, AND METHOD FOR OBTAINING POLYPEPTIDE HAVING ACTIVITY OF RECOMBINANT FACTOR VIII
WO2014018777A2 (en) 2012-07-25 2014-01-30 Biogen Idec Ma Inc. Blood factor monitoring assay and uses thereof
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
EP3943102A1 (en) 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
RS61387B1 (en) 2013-02-15 2021-02-26 Bioverativ Therapeutics Inc Optimized factor viii gene
UY35462A (en) 2013-03-15 2014-10-31 Biogen Idec Inc FORMULATION OF A FACTOR POLYPEPTIDE VIII.
EP2968498A4 (en) 2013-03-15 2016-09-07 Biogen Ma Inc Factor ix polypeptide formulations
WO2015012924A2 (en) 2013-04-29 2015-01-29 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof
EP3013358A4 (en) 2013-06-28 2017-03-22 Biogen MA Inc. Thrombin cleavable linker with xten and its uses thereof
WO2015021423A2 (en) 2013-08-08 2015-02-12 Biogen Idec Ma Inc. Purification of chimeric fviii molecules
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
WO2015023894A1 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Recombinant factor viii proteins
US10611794B2 (en) 2013-09-25 2020-04-07 Bioverativ Therapeutics Inc. On-column viral inactivation methods
MX2016005333A (en) 2013-10-22 2017-02-15 Dbv Tech Method of treating haemophilia by inducing tolerance to blood factors.
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
US9771403B2 (en) 2013-12-09 2017-09-26 Sangamo Therapeutics, Inc. Methods and compositions for treating hemophilia
CN116731201A (en) 2014-01-10 2023-09-12 比奥贝拉蒂治疗公司 Factor VIII chimeric proteins and uses thereof
KR102567586B1 (en) 2014-02-04 2023-08-16 바이오젠 엠에이 인코포레이티드 Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
WO2016012595A1 (en) * 2014-07-25 2016-01-28 Csl Behring Gmbh Improved factor viii preparations suitable for therapeutic use and processes to obtain these
MA40864A (en) 2014-10-31 2017-09-05 Biogen Ma Inc HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES
US10058624B2 (en) 2015-04-16 2018-08-28 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
EP3331608A4 (en) 2015-08-03 2019-05-01 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
AU2017214378B2 (en) 2016-02-01 2023-05-04 Bioverativ Therapeutics Inc. Optimized Factor VIII genes
MA46968A (en) 2016-12-02 2019-10-09 Bioverativ Therapeutics Inc METHODS FOR INDUCTION OF IMMUNE TOLERANCE TO COAGULATION FACTORS
KR20190090827A (en) 2016-12-02 2019-08-02 바이오버라티브 테라퓨틱스 인크. How Chimeric Coagulation Factors Can Be Used to Treat Hemophilic Arthrosis
EP3665289A1 (en) 2017-08-09 2020-06-17 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
CA3077380A1 (en) 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
UY38160A (en) 2018-04-04 2019-11-29 Sigilon Therapeutics Inc IMPLANTABLE PARTICLES AND RELATED METHODS
US20210145889A1 (en) 2018-04-04 2021-05-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
WO2019222682A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
US20200069817A1 (en) 2018-08-09 2020-03-05 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
UY38389A (en) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS
MX2021015897A (en) 2019-06-19 2022-04-18 Bioverativ Therapeutics Inc Recombinant factor viii-fc for treating hemophilia and low bone mineral density.
US20240043494A1 (en) 2020-08-07 2024-02-08 Amicus Therapeutics, Inc. Vesicle Targeting Proteins And Uses Of Same
KR20240049332A (en) 2021-08-23 2024-04-16 바이오버라티브 테라퓨틱스 인크. Optimized factor VIII gene
IL311725A (en) 2021-09-30 2024-05-01 Bioverativ Therapeutics Inc Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR910006424B1 (en) * 1985-08-21 1991-08-24 인코텍스 비.브이 Method of manufacturing knitted briefs
EP0253870B1 (en) * 1986-01-03 1993-03-31 Genetics Institute, Inc. Method for producing factor viii:c-type proteins
EP0251843A1 (en) * 1986-06-06 1988-01-07 Transgene S.A. Process for the preparation of factor VIII from mammalian cells
JPH0637425B2 (en) * 1986-11-11 1994-05-18 株式会社クラレ Method for producing high boiling point (meth) acrylic acid ester
FR2619314B1 (en) * 1987-08-11 1990-06-15 Transgene Sa FACTOR VIII ANALOG, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
JP2586092B2 (en) * 1988-04-06 1997-02-26 三菱瓦斯化学株式会社 Method for producing polyfunctional (meth) acrylate
DK0500734T3 (en) * 1989-11-17 1998-03-30 Chiron Corp Protein complexes with factor VIII: C activity as well as their production

Also Published As

Publication number Publication date
EP0506757B2 (en) 2005-10-26
SE465222C5 (en) 1998-02-10
DK0506757T3 (en) 1999-05-25
DE69032600T3 (en) 2006-07-20
EP1293513A3 (en) 2003-04-02
BR9007921A (en) 1992-11-10
AU7039391A (en) 1991-07-18
NL990035I2 (en) 2000-01-03
HU211504A9 (en) 1995-11-28
ES2189897T3 (en) 2003-07-16
DE69034040T2 (en) 2003-11-20
SE465222B (en) 1991-08-12
WO1991009122A1 (en) 1991-06-27
SE8904239D0 (en) 1989-12-15
NO922325D0 (en) 1992-06-12
DK0506757T4 (en) 2006-02-20
DK0786474T3 (en) 2003-03-03
CA2071875C (en) 2006-08-08
AU645539B2 (en) 1994-01-20
EP0786474B1 (en) 2003-02-05
CA2071875A1 (en) 1991-06-16
SG66753A1 (en) 2001-12-19
FI104260B (en) 1999-12-15
EP1293513A2 (en) 2003-03-19
DE69032600T2 (en) 1999-01-07
DE69034040D1 (en) 2003-03-13
ES2119769T5 (en) 2006-04-16
ATE232213T1 (en) 2003-02-15
PT96208B (en) 1998-05-29
EP0786474A1 (en) 1997-07-30
JPH05502161A (en) 1993-04-22
NZ236276A (en) 1993-03-26
DE19975066I2 (en) 2005-07-07
FI922745A0 (en) 1992-06-12
NL990035I1 (en) 1999-12-01
IE904510A1 (en) 1991-07-17
SE8904239L (en) 1991-06-16
ES2119769T3 (en) 1998-10-16
NO309041B1 (en) 2000-12-04
PT96208A (en) 1991-09-30
JP2644084B2 (en) 1997-08-25
EP0506757A1 (en) 1992-10-07
LU90457I2 (en) 2001-04-13
HK1019449A1 (en) 2000-02-11
FI104260B1 (en) 1999-12-15
NO922325L (en) 1992-08-11
ATE170219T1 (en) 1998-09-15
EP0506757B1 (en) 1998-08-26
DE69032600D1 (en) 1998-10-01

Similar Documents

Publication Publication Date Title
HK1009290A1 (en) A recombinant human factor viii derivative
SE9100799L (en) HUMAN FACTOR RECOMBINANT DERIVATIVE VIII
DE69429176D1 (en) Protegrine
NO971621L (en) Keratinocyttvekstfaktoranaloger
AU1431188A (en) Dihydropyridine - pyridinium salt-type redox amino acids and peptides containing them
EP0528686A3 (en)
ATE86260T1 (en) PEPTIDE MOLECULES EFFECTIVE AGAINST GRAM-POSITIVE GERMS.
Kondo et al. Synthesis of enkephalin analog with leucinthiol at C-terminus as probe for thiol group in opiate receptors

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20101205